BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
AMBROSETTI, Achille;
2015-01-01
Abstract
BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
nejmoa1506583.pdf
accesso aperto
Tipologia:
Versione dell'editore
Licenza:
Dominio pubblico
Dimensione
986.27 kB
Formato
Adobe PDF
|
986.27 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
